Compare
DaVita Inc. vs agilon health, inc. vs Progyny, Inc. vs Sotera Health Co
| Latest fiscal year | DaVita Inc. DVA | agilon health, inc. AGL | Progyny, Inc. PGNY | Sotera Health Co SHC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $13.64B | $5.93B | $1.29B | $1.16B |
| Revenue growth (YoY) | +6.5% | -2.1% | +10.4% | +5.7% |
| Gross margin | n/a | n/a | 23.6% | 55.5% |
| Operating margin | 15.0% | -7.8% | 6.6% | n/a |
| Net margin | 5.5% | -6.6% | 4.5% | 6.7% |
| Net income | $746.80M | -$391.35M | $58.52M | $77.95M |
| EPS (Diluted) | $9.84 | n/a | $0.65 | $0.27 |
| Operating cash flow | $1.89B | -$105.76M | $210.19M | $287.19M |
| Free cash flow | $1.31B | -$119.00M | $191.78M | $149.18M |
| Cash & equivalents | $676.44M | $173.71M | $112.24M | $344.62M |
| Total assets | $17.48B | $1.27B | $742.43M | $3.26B |
| Total liabilities | $16.32B | $1.14B | $226.39M | $2.66B |
| Shareholders' equity | -$651.08M | $126.73M | $516.04M | $606.03M |
| Return on year-end equity | n/a | -308.8% | 11.3% | 12.9% |
| Shares outstanding | 68.55M | 414.73M | 83.37M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | DaVita Inc. | agilon health, inc. | Progyny, Inc. | Sotera Health Co |
|---|---|---|---|---|
| Latest | $13.64B Ended 2025-12-31 | $5.93B Ended 2025-12-31 | $1.29B Ended 2025-12-31 | $1.16B Ended 2025-12-31 |
| 1 year earlier | $12.82B Ended 2024-12-31 | $6.06B Ended 2024-12-31 | $1.17B Ended 2024-12-31 | $1.10B Ended 2024-12-31 |
| 2 years earlier | $12.14B Ended 2023-12-31 | $4.32B Ended 2023-12-31 | $1.09B Ended 2023-12-31 | $1.05B Ended 2023-12-31 |
| 3 years earlier | $11.61B Ended 2022-12-31 | $2.39B Ended 2022-12-31 | $786.91M Ended 2022-12-31 | $1.00B Ended 2022-12-31 |
| 4 years earlier | $11.62B Ended 2021-12-31 | $1.52B Ended 2021-12-31 | $500.62M Ended 2021-12-31 | $931.48M Ended 2021-12-31 |